UA34419C2 - Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин - Google Patents

Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин

Info

Publication number
UA34419C2
UA34419C2 UA5010680A UA5010680A UA34419C2 UA 34419 C2 UA34419 C2 UA 34419C2 UA 5010680 A UA5010680 A UA 5010680A UA 5010680 A UA5010680 A UA 5010680A UA 34419 C2 UA34419 C2 UA 34419C2
Authority
UA
Ukraine
Prior art keywords
growth inhibition
injectable preparation
tumour growth
lyophilised
lyophilised injectable
Prior art date
Application number
UA5010680A
Other languages
English (en)
Russian (ru)
Inventor
Гаетано Гатті
Гаэтано Гатти
Дієго ОЛДАНІ
Диего Олдани
Карло КОНФАЛОНІЄРІ
Карло Конфалониери
Лучіано Гамбіні
Лучиано Гамбини
Original Assignee
Фармація Енд Апджон С.П.А.
Фармация Энл Апджон С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармація Енд Апджон С.П.А., Фармация Энл Апджон С.П.А. filed Critical Фармація Енд Апджон С.П.А.
Publication of UA34419C2 publication Critical patent/UA34419C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Даний винахід стосується стабільних, швидкорозчинних, ліофілізованих, придатних для ін’єкцій препаратів, що містять глікозид антрацикліну або його фармацевтично прийнятну сіль як активного лікарського засобу, а також застосування вказаних препаратів для лікування пухлин.
UA5010680A 1984-10-22 1985-10-18 Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин UA34419C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848426672A GB8426672D0 (en) 1984-10-22 1984-10-22 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
UA34419C2 true UA34419C2 (uk) 2001-03-15

Family

ID=10568553

Family Applications (2)

Application Number Title Priority Date Filing Date
UA5010680A UA34419C2 (uk) 1984-10-22 1985-10-18 Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
UA3964940A UA19169A (uk) 1984-10-22 1985-10-18 Спосіб одержаhhя порошку ліофілізоваhого аhтрацикліh глікозиду

Family Applications After (1)

Application Number Title Priority Date Filing Date
UA3964940A UA19169A (uk) 1984-10-22 1985-10-18 Спосіб одержаhhя порошку ліофілізоваhого аhтрацикліh глікозиду

Country Status (35)

Country Link
US (4) US4675311A (uk)
JP (1) JPH0611700B2 (uk)
KR (1) KR920005813B1 (uk)
CN (1) CN85107562B (uk)
AT (1) AT401345B (uk)
AU (1) AU572003B2 (uk)
BE (1) BE903484A (uk)
BG (1) BG60934B2 (uk)
CA (1) CA1248453A (uk)
CH (1) CH667594A5 (uk)
CS (1) CS270421B2 (uk)
DE (1) DE3536896C2 (uk)
DK (1) DK165620C (uk)
ES (1) ES8605374A1 (uk)
FI (2) FI853913A7 (uk)
FR (1) FR2571966B1 (uk)
GB (2) GB8426672D0 (uk)
GR (1) GR852549B (uk)
HK (1) HK94390A (uk)
HU (1) HU197988B (uk)
IE (1) IE56992B1 (uk)
IL (1) IL76732A (uk)
IT (1) IT1186779B (uk)
MY (1) MY103956A (uk)
NL (1) NL191308C (uk)
NO (1) NO170616C (uk)
NZ (1) NZ213885A (uk)
PH (1) PH23982A (uk)
PT (1) PT81347B (uk)
RU (2) RU1836088C (uk)
SE (1) SE467520B (uk)
SG (1) SG80290G (uk)
UA (2) UA34419C2 (uk)
YU (1) YU46160B (uk)
ZA (1) ZA858033B (uk)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124317A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124318A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
IT1226072B (it) * 1986-12-05 1990-12-10 Erba Farmitalia Soluzioni iniettabili pronte all'uso contenenti un glicoside antraciclinico antitumorale.
JP2603480B2 (ja) * 1987-08-05 1997-04-23 住友製薬株式会社 安定化されたアンスラサイクリン系製剤
DE3801178A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
RU2292216C2 (ru) * 2000-10-31 2007-01-27 Фарма Мар, С.А. Кахалалид f
ATE397440T1 (de) 2002-02-22 2008-06-15 Schering Corp Pharmazeutische zubereitungen von antineoplastischen wirkstoffen, insbesondere temozolomid, verfahren zu ihrer herstellung und deren verwendung
DK1474995T3 (da) * 2003-05-06 2013-02-18 Gumlink As Fremgangsmåde til fremstilling af tyggegummigranulater, et gummisammensætningsekstruder- og granuleringssystem og et tyggegummiprodukt
DE04777189T1 (de) * 2003-07-02 2011-04-07 Solux Corporation, San Diego Thermisch stabiles kristallines epirubicin-hydrochlorid und herstellungsverfahren dafür
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
CA2540108A1 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
US7388083B2 (en) * 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
WO2006122309A2 (en) * 2005-05-11 2006-11-16 Sicor, Inc. Stable lyophilized anthracycline glycosides
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
DE06848583T1 (de) * 2005-12-13 2011-03-17 Solux Corporation, San Diego Verfahren zur herstellung von 4-demethyldaunorubicin
US8802830B2 (en) * 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
JP5634862B2 (ja) * 2007-05-16 2014-12-03 カーテーベー トゥモーアフォルシュングス ゲゼルシャフト ミット ベシュレンクテル ハフツング 低粘度アントラサイクリン製剤
US8227430B2 (en) 2007-09-04 2012-07-24 Meiji Seika Pharma Co., Ltd Injectable, injection solution, and injection kit preparation
CA2703149A1 (en) * 2007-10-26 2009-04-30 Pfizer Products Inc. Idarubicin for the treatment of lymphoma in a dog
US8357785B2 (en) * 2008-01-08 2013-01-22 Solux Corporation Method of aralkylation of 4′-hydroxyl group of anthracylins
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
MX2012008171A (es) * 2010-01-15 2012-12-17 Lithera Inc Formulaciones aglomeradas liofilizadas.
EP2646012A4 (en) 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT
DE102011103751A1 (de) 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
JP6433913B2 (ja) 2012-12-13 2018-12-05 サイトレックス コーポレイション アントラサイクリン製剤
NZ631022A (en) 2013-06-05 2018-05-25 Cytrx Corp Cytotoxic agents for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4039663A (en) * 1975-03-19 1977-08-02 Societa' Farmaceutici Italia S.P.A. Daunomycins, process for their uses and intermediates
GB1506200A (en) * 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
GB1567456A (en) * 1976-11-16 1980-05-14 Farmaceutici Italia Daunomycin derivatives
GB2007645B (en) * 1977-10-17 1982-05-12 Stanford Res Inst Int Benzyl anthracyclines and pharmaceutical compositions containing them
US4177264A (en) * 1977-10-17 1979-12-04 Sri International N-benzyl anthracyclines
JPS563851A (en) * 1979-06-22 1981-01-16 Matsushita Electric Works Ltd Fireplace in floor
JPS5756494A (en) * 1980-09-22 1982-04-05 Microbial Chem Res Found New anthracyclin derivative
US4325947A (en) * 1981-05-12 1982-04-20 Farmitalia Carlo Erba S.P.A. 4-Demethoxy-4'-deoxydoxorubicin
IT1210476B (it) * 1981-05-28 1989-09-14 Erba Farmitalia Antracicline.
US4438105A (en) * 1982-04-19 1984-03-20 Farmaitalia Carlo Erba S.P.A 4'-Iododerivatives of anthracycline glycosides
FI75834C (fi) * 1982-05-24 1988-08-08 Erba Farmitalia Foerfarande foer framstaellning av antracyklinglykosidfoereningar.
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
CA1248944A (en) * 1982-09-28 1989-01-17 Gareth J. Thomas Anthracycline glycosides
JPS5982395A (ja) * 1982-11-02 1984-05-12 Microbial Chem Res Found アントラサイクリン化合物、その製造法およびその用途
GR79729B (uk) * 1982-12-20 1984-10-31 Univ Ohio State Res Found
JPS6092212A (ja) * 1983-10-26 1985-05-23 Kyowa Hakko Kogyo Co Ltd ドキソルビシン塩の製剤
US4537882A (en) * 1984-05-10 1985-08-27 Ohio State University 4-Demethoxy-3'-desamino-2'-halo-anthracycline and pharmaceutical composition containing same

Also Published As

Publication number Publication date
ATA303285A (de) 1996-01-15
YU164485A (en) 1987-10-31
NO170616B (no) 1992-08-03
NL191308C (nl) 1995-05-16
US4840938A (en) 1989-06-20
DK481585D0 (da) 1985-10-21
NL8502869A (nl) 1986-05-16
NO170616C (no) 1992-11-11
HK94390A (en) 1990-11-23
IE56992B1 (en) 1992-02-26
CH667594A5 (de) 1988-10-31
NO854194L (no) 1986-04-23
GB8525709D0 (en) 1985-11-20
AT401345B (de) 1996-08-26
ES547578A0 (es) 1986-03-16
BG60934B2 (bg) 1996-06-28
MY103956A (en) 1993-10-30
SE8504945L (sv) 1986-04-23
BE903484A (fr) 1986-04-21
CN85107562B (zh) 1988-06-01
JPS61246129A (ja) 1986-11-01
YU46160B (sh) 1993-05-28
IT8522507A0 (it) 1985-10-16
FI853913A0 (fi) 1985-10-08
CS756585A2 (en) 1989-11-14
RU2101018C1 (ru) 1998-01-10
SG80290G (en) 1990-11-23
DE3536896A1 (de) 1986-04-24
US5091373A (en) 1992-02-25
ZA858033B (en) 1986-06-25
GB2165751A (en) 1986-04-23
GR852549B (uk) 1986-02-24
DK481585A (da) 1986-04-23
PT81347B (pt) 1987-11-11
FI854035L (fi) 1986-04-23
AU572003B2 (en) 1988-04-28
FI86252B (fi) 1992-04-30
GB2165751B (en) 1988-08-17
GB8426672D0 (en) 1984-11-28
IT1186779B (it) 1987-12-16
FR2571966B1 (fr) 1988-04-15
DK165620C (da) 1993-06-01
AU4880585A (en) 1986-05-01
US4675311A (en) 1987-06-23
CS270421B2 (en) 1990-06-13
RU1836088C (ru) 1993-08-23
HU197988B (en) 1989-07-28
KR920005813B1 (ko) 1992-07-20
PH23982A (en) 1990-02-09
NZ213885A (en) 1988-05-30
UA19169A (uk) 1997-12-25
SE8504945D0 (sv) 1985-10-21
DK165620B (da) 1992-12-28
NL191308B (nl) 1994-12-16
CA1248453A (en) 1989-01-10
DE3536896C2 (de) 1996-11-14
FI86252C (fi) 1992-08-10
IE852593L (en) 1986-04-22
FR2571966A1 (fr) 1986-04-25
IL76732A0 (en) 1986-02-28
JPH0611700B2 (ja) 1994-02-16
ES8605374A1 (es) 1986-03-16
SE467520B (sv) 1992-08-03
KR860003014A (ko) 1986-05-19
US5091372A (en) 1992-02-25
PT81347A (en) 1985-11-01
CN85107562A (zh) 1986-07-23
FI854035A0 (fi) 1985-10-16
IL76732A (en) 1989-07-31
FI853913A7 (fi) 1986-04-23
HUT40759A (en) 1987-02-27

Similar Documents

Publication Publication Date Title
HK94390A (en) Pharmaceutical compositions containing anthracycline glycosides
EP0395329A3 (en) composition in the form of a foam containing 5-aminosalicylic acid for intra-rectal administration
HUT58511A (en) Process for producing pharmaceutical compositions comprising toremifen and its metabolites, suitable for ceasing the simultaneous resistance of cancer cells to several cytotoxic active ingredients
ATE66614T1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
AU2789989A (en) Acylated uridine and cytidine and uses thereof
CA2291065A1 (en) Raf kinase inhibitors
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
HU9302496D0 (en) Method for producing anti-viral nucleoside combinations and one for preparing medical preparatives containing said compounds
PT86186A (en) Process for the preparation of benzimidazol derivatives and of pharmaceutical compositions containing the same
BG103647A (en) Cisplatina containing microgranules
MY109309A (en) Improvements in or relating to somatostatins
MY102549A (en) Crystalline calcium pseudomonate and a process for preparing the same and its use as a pharmaceutical composition
ES8800601A1 (es) Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
HUT63769A (en) Process for producing pharmaceutical compositions comprising il-4 as active ingredient and suitable for treating thick tumours
HK93990A (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
GB1395090A (en) Stabilized hormone compositions
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
AU7999787A (en) Active compounds for use in the treatment of tumors
FI871545A7 (fi) Menetelmä syövän hoitoon käytettävän synergistisen seoksen valmistamiseksi, joka sisältää interleukiini-2:ta ja/tai interferoni- :aa ja kasvainnekroositekijää.
GB1474424A (en) Pharmaceutical composition for treating diabetic ketoacidosis
CA2283739A1 (en) Ascorbic acid as an adjuvant in treatment of malignant tumors by chemotherapy and radiotherapy
ES8801624A1 (es) Procedimiento para preparar disulfuros heterociclicos
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere